Prot#AK002-003: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis